Last reviewed · How we verify
Vancomycin capsules
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA.
At a glance
| Generic name | Vancomycin capsules |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | glycopeptide antibiotic |
| Target | D-alanyl-D-alanine terminus of cell wall precursors |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin is a glycopeptide antibiotic that is effective against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Approved indications
- Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Anemia
- Thrombocytopenia
- Renal impairment
- Hypokalemia
- Hypomagnesemia
- Tinnitus
Key clinical trials
- Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection (PHASE2)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients (PHASE1, PHASE2)
- A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis (PHASE1)
- Intestinal Microbiome Transplant in ALS (PHASE1, PHASE2)
- Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |